Abstract:Muscle wasting is often associated with chronic inflammation. Because tumor necrosis factor ␣ (TNF-␣) has been implicated as a major mediator of cachexia, its effects on C2C12 myocytes were examined. TNF-␣ activated nuclear factor-␬B (NF-␬B) and interfered with the expression of muscle proteins in differentiating myoblasts. Introduction of a mutant form of inhibitory protein ␬B␣ (I␬B␣) restored myo-genic differentiation in myoblasts treated with TNF-␣ or interleukin 1␤. Conversely, activation of NF-␬B by overexpression of I␬B kinase was sufficient to block myogenesis, illustrating the causal link between NF-␬B activation and inhibition of myogenic differentiation. The inhibitory effects of TNF-␣ on myogenic differentiation were reversible, indicating that the effects of the cytokine were not due to nonspecific toxicity. Treatment of differentiated myotubes with TNF-␣ did not result in a striking loss of muscle-specific proteins, which shows that myogenesis was selectively affected in the myoblast stage by TNF-␣. An important finding was that NF-␬B was activated to the same extent in differentiating and differentiated cells, illustrating that once myocytes have differentiated they become refractory to the effects of NF-␬B activation. These results demonstrate that inflammatory cytokines may contribute to muscle wasting through the inhibition of myogenic differentiation via a NF-␬B-dependent pathway.—Lan-matory cytokines inhibit myogenic differentiation through activation of nuclear factor-␬B. Muscle wasting, defined as the loss of skeletal muscle tissue, commonly occurs in chronic wasting syndromes, such as AIDS (1), cancer (2), chronic heart failure (3), and chronic obstructive pulmonary disease (4 – 6), and is an independent predictor of mortality. Remarkably, in many of these conditions muscle wasting is associated with chronic elevations in circulating inflamma-tory cytokines, in particular tumor necrosis factor ␣ (TNF-␣) (7–10). Muscle wasting is generally believed to result from disturbances in the energy or anabolism-catabolism balance. For example, imbalances in myofi-brillar protein synthesis and proteolysis have been demonstrated in experimental models of cancer ca-chexia (11, 12) and sepsis (13). Elevated levels of circulating inflammatory mediators, such as TNF-␣ and interleukin 1 (IL-1), were believed to trigger the events leading to muscle wasting in these models. In support of this, chronic administration of TNF-␣ or IL-1 induced weight loss and skeletal muscle wasting in rats (14). Muscle wasting may alternatively result from a decrease of the number of fibers. In support of this proposal, an increased prevalence of apoptotic myonu-clei has been associated with the loss of skeletal muscle tissue in muscular dystrophies and inflammatory myop-athies (15–17). In addition, …

Reduced myotube diameter induced by combined inhibition of transforming growth factor‐β type I receptors Acvr1b and Tgfbr1 is associated with enhanced β1‐syntrophin expression

Myofibre-specific knockout of TGF-β type I receptors triggers muscle hypertrophy and promotes contraction and oxidative metabolism

Functional redundancy of type I and type II receptors in the regulation of skeletal muscle growth by myostatin and activin A

Blocking of Myostatin and Activins Increase Muscle Protein Synthesis and Mtorc1 Signaling but Decreases Capillary Density

Myostatin inhibition promotes fast fibre hypertrophy but causes loss of AMP-activated protein kinase signalling and poor exercise tolerance in a model of limb-girdle muscular dystrophy R1/2A

Muscle hypertrophy induced by myostatin inhibition accelerates degeneration in dysferlinopathy

Biomechanical signals upregulate myogenic gene induction in the presence or absence of inflammation

Mice overexpressing growth hormone exhibit increased skeletal muscle myostatin and MuRF1 with attenuation of muscle mass

HMGB1/autophagy Pathway Mediates the Atrophic Effect of TGF-β1 in Denervated Skeletal Muscle

TAK-1/p38/nNFκB signaling inhibits myoblast differentiation by increasing levels of Activin A

Differential Response of Skeletal Muscles to Mtorc1 Signaling During Atrophy and Hypertrophy

Tuning Macrophage Phenotype to Mitigate Skeletal Muscle Fibrosis

TAK1 Inhibition Improves Myoblast Differentiation and Alleviates Fibrosis in a Mouse Model of Duchenne Muscular Dystrophy

Activin A more prominently regulates muscle mass in primates than does GDF8

Muscle Protein Synthesis, Mtorc1/Mapk/Hippo Signaling, and Capillary Density Are Altered by Blocking of Myostatin and Activins

mTORC1 and BMP-Smad1/5 regulation of serum-stimulated myotube hypertrophy: a role for autophagy

Inflammatory Cytokines Inhibit Myogenic Differentiation through Activation of Nuclear Factor-␬b

Inflammatory Cytokine-Induced Muscle Atrophy and Weakness Can Be Ameliorated by an Inhibition of TGF-β-Activated Kinase-1

Blockade of activin type II receptors with a dual anti-ActRIIA/IIB antibody is critical to promote maximal skeletal muscle hypertrophy

An antibody blocking activin type II receptors induces strong skeletal muscle hypertrophy and protects from atrophy

TMEPAI/PMEPA1 Is a Positive Regulator of Skeletal Muscle Mass